INCY News and Press, Incyte Corporation From 03/30/22

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies PR Newswire New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today INDIANAPOL...

- Use of ruxolitinib cream (Opzelura™) resulted in further improvement in facial and total body repigmentation at Week 52 - Results will be featured as an oral presentation in a late-breaking abstract session at the 2022 American Academy of Dermatology (AAD) Annual Meet...

A committee of the European Medicines Agency (EMA) recommended the approval for expanded use of Incyte (NASDAQ:INCY) and Novartis' Jakavi (ruxolitinib) to treat patients aged 12 years and older with acute graft-versus-host disease or chronic graft-versus-host disease (GVHD) who have inad...

The positive opinion from the CHMP is based on data from the Phase 3 REACH2 and REACH3 trials, which demonstrated that ruxolitinib (Jakavi ® ) improved response rates and failure-free survival compared to best available therapy, which provides a promising opportunity for pa...

It is difficult to know accurately what the world will look like 10 years from now, but some predictions seem relatively safe. Here are just two examples. First, in a decade, equity markets will be up from their current levels. Second, the need for lifesaving medicines won't have subsid...

MorphoSys (NASDAQ:MOR) and partner Incyte (INCY) said the Swissmedic had granted temporary approval for their combination therapy, Minjuvi (tafasitamab) to treat relapsed or refractory diffuse large B-cell lymphoma. Minjuvi is given to DLBCL patinets in combination with Celgene...

The core business looks solid. Opzelura's sales start is impressive, but revenue is low due to high discounts. The potential approval in vitiligo indication could be the next growth driver. I remain bullish on the company stock. For further details see: Incyte: All A...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

New data on ruxolitinib cream (Opzelura™) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking oral presentation Incyte (Nasdaq:INCY) today announced that ...